Type2MI

Type 2 MI / demand ischemia · complete reference · all trials · full doses + brand names · Full Card

Symptoms / Associated Sx

• Often no chest pain — troponin elevation discovered incidentally on routine workup in context of another acute illness; primary illness symptoms dominate the presentation

• If chest symptoms present: non-specific pressure or discomfort without classic crescendo anginal pattern; symptoms often paralleled by the severity of the precipitating illness

• Precipitant symptoms dominate: fever/rigors/hypotension (sepsis/bacteremia — most common inpatient Type 2 MI precipitant); rapid irregular palpitations (AF-RVR); dyspnea + hypoxemia (respiratory failure/PE); symptoms of severe anemia (dyspnea on minimal exertion, weakness, pallor, tachycardia)

• Warning signs of Type 1 component: classic ischemic chest pain independent of or disproportionate to illness severity; new focal neurologic symptoms (stroke as ACS complication); troponin elevation >20× URL; hemodynamic instability that does not improve with precipitant treatment

• Takotsubo (stress CM): emotional or physical stressor (hospitalization, surgery, neurologic event, emotional trauma); transient apical ballooning on echo; diffuse deep T-wave inversions; usually older women; EF recovers 4–6 weeks; normal coronaries on cath; recurrence risk 1.5–2% per year

Neg

• Pt denies classic crescendo substernal pressure with arm/jaw/neck radiation independent of illness severity — argues against Type 1 MI/NSTEMI (if classic ischemic symptoms cannot be excluded, manage as NSTEMI; cardiology consult + serial troponin with ECG monitoring; lower threshold for cath in patients with severe underlying CAD)

• Pt denies STE ≥1 mm in a focal coronary territory or STEMI equivalents (new LBBB + Sgarbossa criteria, de Winter T-waves, posterior STEMI pattern) — argues against STEMI (STEMI requires cath lab activation regardless of apparent precipitant; do not be distracted by a clear precipitant and miss a concurrent STEMI)

• Pt denies new focal/regional wall motion abnormality in a specific coronary territory on bedside echo — argues against Type 1 ischemic process (focal/regional WMA in coronary territory = Type 1 until proven otherwise; global LV dysfunction = demand/sepsis/Takotsubo pattern consistent with Type 2)

• Pt denies viral prodrome + diffuse non-territorial ECG changes without coronary territory distribution + markedly elevated troponin without clear hemodynamic precipitant — argues against myocarditis (cardiac MRI: LGE in non-ischemic subepicardial or midmyocardial pattern; treat myocarditis: restriction from exercise + NSAIDs/colchicine [Colcrys] for inflammation; avoid immunosuppression unless giant cell myocarditis)

• Pt denies blunt anterior chest trauma within hours of troponin elevation (cardiac contusion — supportive; no intervention; monitor for arrhythmias; echo for wall motion)

Social History (SHx)

• Severity and duration of precipitating illness before troponin discovered; known CAD severity (prior cath anatomy — severe obstructive CAD severely limits coronary reserve; Type 2 MI at milder physiologic stress levels in severe CAD = very high-risk patients); prior Type 2 MI episodes

• Medications: vasoconstrictors (decongestants, stimulants, cocaine, ergotamines — coronary vasospasm); tachycardia-promoting agents (thyroid hormone, stimulants, albuterol [Proventil]); anemia history + prior transfusions; prior surgery type and timing

Main Etiology

• Demand ↑ (↑myocardial O2 demand): tachyarrhythmia (AF-RVR most common inpatient trigger — ↑HR → ↓diastolic filling time → ↓coronary perfusion + ↑O2 consumption); sepsis/fever (↑metabolic demand + cytokine-mediated myocardial depression + microvascular dysfunction); HTN emergency (↑afterload → ↑wall stress → ↑O2 demand); cocaine (catecholamine surge + coronary vasospasm + HTN + tachycardia)

• Supply ↓ (↓myocardial O2 delivery): severe anemia (Hgb <7–8 g/dL → ↓O2-carrying capacity → ↓myocardial O2 delivery); severe hypotension (MAP <65 → ↓coronary perfusion pressure → subendocardial ischemia); severe hypoxemia (SpO2 <80% → ↓arterial O2 content → ↓myocardial O2 delivery); coronary vasospasm/Prinzmetal angina (↑coronary tone → ↓blood flow without plaque rupture)

• Mixed mechanisms: cardiogenic shock (↓coronary perfusion + ↑wall stress + ↑demand in ischemic areas); post-cardiac surgery (CPB-related microvascular injury + reperfusion injury + demand during weaning); major non-cardiac surgery (perioperative hemodynamic stress + catecholamine surge)

• Special subtypes: Takotsubo CM (catecholamine-mediated apical stunning — emotional/physical stressor → massive catecholamine surge → apical myocardial stunning with preserved basal function; normal coronaries); MINOCA with vasospasm

RF

• Primary RF: pre-existing obstructive CAD (most important — limits coronary reserve; severe CAD patients experience Type 2 MI at milder physiologic stress; prior cath anatomy should be reviewed at every Type 2 MI admission)

• Systemic illness RF: sepsis and bacteremia (most common inpatient trigger); major non-cardiac surgery (perioperative MI in 5% of high-risk patients); major trauma/burns; ARDS; acute respiratory failure requiring mechanical ventilation

• Demand/supply RF: chronic anemia (sickle cell disease — sickle cell crisis associated with Type 2 MI); AF with poorly controlled ventricular rate; severe HTN; cocaine/stimulant use; untreated severe OSA (nocturnal hypoxemia → demand ischemia)

Data

• Serial troponin I/T q6–8h (kinetic pattern is diagnostic: Type 2 = modest rise + clear systemic precipitant + declining within 12–24h of adequate precipitant treatment; Type 1 = disproportionately high rise OR failing to decline at 12–24h despite treated precipitant; troponin >20× URL suggests Type 1 mechanism regardless of apparent precipitant — seek Type 1; single troponin value cannot distinguish Type 1 from Type 2 — kinetics required)

• Serial ECG (admission + daily + with any symptom change) (diffuse non-specific ST/T changes = demand/Type 2 pattern; focal territorial STE ≥1 mm in ≥2 contiguous leads = Type 1 → STEMI protocol; focal ST↓ in specific coronary territory = Type 1 NSTEMI → cardiology; new LBBB = STEMI equivalent; always compare to prior ECG)

• Bedside echo (global LV dysfunction [diffuse hypokinesis] = consistent with sepsis-induced cardiomyopathy or Takotsubo; focal/regional WMA in a coronary territory = Type 1 ischemic process → cardiology urgently; new MR (papillary muscle ischemia); pericardial effusion; RV function; IVC — volume status)

• CBC with differential (Hgb — anemia severity; trigger threshold Hgb <7–8 g/dL for transfusion in Type 2 MI context [MINT 2023: Hgb ≥10 target in ACS]; WBC with differential — infection trigger; leukocytosis + left shift + bands = bacteremia/sepsis)

• Lactate serial q4–6h (tissue hypoperfusion in sepsis or cardiogenic shock; lactate >2 = ↑mortality; serial clearance monitors treatment response; failure to clear = inadequate resuscitation)

• Blood cultures ×2 (before antibiotics) (mandatory if sepsis suspected as precipitant; draw from 2 separate sites before ANY antibiotics; bottle type: aerobic + anaerobic; volume 10 mL each bottle; sensitivity 70–90% for bacteremia)

• BMP (Cr — vasopressor-related AKI + worsening Cr ↑Type 2 MI mortality; K+ — arrhythmia risk in tachycardia-mediated Type 2 MI; Na+ — prognostic if HF; glucose — stress hyperglycemia in sepsis)

• BNP or NT-proBNP (LV dysfunction from demand ischemia; elevated in Takotsubo; sepsis-induced cardiomyopathy; guides fluid management in borderline hemodynamic states)

• Cardiac MRI (for MINOCA or uncertainty) (if troponin elevated + normal coronaries on cath [MINOCA]: LGE in ischemic subendocardial pattern = true ischemic MINOCA [vasospasm/embolism]; LGE in non-ischemic subepicardial/midmyocardial = myocarditis; T1/T2 mapping for edema = myocarditis; no LGE + apical ballooning pattern = Takotsubo; perform within 1 week of presentation)

DDx

Type 1 MI / NSTEMI / STEMI (classic ischemic sx independent of illness; focal territorial ECG; troponin disproportionate to illness; regional WMA on echo; DAPT + anticoag + invasive strategy — the critical distinction; most consequential decision in Type 2 MI management) · Myocarditis (viral prodrome; diffuse non-territorial ECG; markedly elevated troponin without hemodynamic precipitant; cardiac MRI: LGE non-ischemic subepicardial) · PE (pleuritic CP + hypoxia + tachycardia + RV dilation on echo — RV strain pattern; CT-PA confirms) · Takotsubo CM (stressor; apical ballooning echo; diffuse deep TWI; normal coronaries; EF recovers 4–6 weeks — Type 2 MI subtype) · Sepsis-induced CM (global LV dysfunction + ↑troponin in bacteremia — troponin independent predictor of mortality in sepsis; treat sepsis) · Cardiac contusion (blunt chest trauma; ECG changes + troponin; supportive only — no DAPT or intervention)

Home Meds

• Continue: aspirin (Bayer/Ecotrin) 81 mg PO daily if on (reasonable in presence of CAD RFs; low bleed risk); atorvastatin (Lipitor) or rosuvastatin (Crestor) — continue or initiate; BB (carvedilol [Coreg]/metoprolol succinate [Toprol-XL]) if prescribed for CAD or HF

• Do NOT add: P2Y12 (clopidogrel [Plavix]/ticagrelor [Brilinta]/prasugrel [Effient]) without cath-confirmed obstructive CAD treated with PCI (no RCT evidence for DAPT in Type 2 MI; ↑bleeding risk in common precipitants: GI bleed, post-surgery, sepsis)

• Treat precipitating illness medications first: broad-spectrum antibiotics if sepsis; vasopressors if hemodynamically unstable; rate control if AF-RVR; transfuse if severe anemia

Plan

• Step 1 — Identify and treat precipitant (primary intervention): treating the precipitant IS the treatment for Type 2 MI; urgent coronary angiography is NOT indicated unless Type 1 MI cannot be excluded after serial monitoring | Most dangerous clinical error: ordering urgent cath for every troponin elevation in hospitalized patients; Type 2 MI is the most common MI type in non-cardiac hospitalized patients; reflexive cath → contrast nephropathy + vascular access complications + unnecessary DAPT + ↑bleeding in ill patients

• AF-RVR: rate control per EF (see AfibRVR card); goal HR <80–110 bpm; troponin should decline within 12–24h of adequate rate control; if troponin continues rising after rate control achieved → re-evaluate for Type 1 component

• Sepsis (most common inpatient Type 2 MI precipitant): blood cultures ×2 from separate sites → broad-spectrum antibiotics within 1h (Surviving Sepsis Campaign 2021 hour-1 bundle); source control urgently (drain abscess, remove infected line, surgical consult if indicated); norepinephrine (Levophed) 0.01–0.5 mcg/kg/min IV if MAP <65 (SOAP II: preferred over dopamine [Intropin] — ↓arrhythmia); crystalloid 30 mL/kg IV if hypotensive + not volume overloaded (SMART trial: balanced crystalloid preferred over NS); serial lactate clearance q4–6h; troponin in sepsis: independent predictor of mortality (OR ~2–3); elevated in up to 60% of septic patients; mechanism: cytokine-mediated injury + microvascular dysfunction + ↑demand; treatment = sepsis management

• Severe anemia (Hgb <7–8 g/dL): pRBC transfusion 1 unit → recheck Hgb; target Hgb ≥8 g/dL minimum; in ACS context: target Hgb ≥10 g/dL (MINT trial 2023, NEJM: liberal transfusion [Hgb ≥10 g/dL] ↓30-day MACE vs restrictive [Hgb ≥8 g/dL]: 14.6% vs 16.7%; NNT 50); address underlying cause (iron deficiency → ferric carboxymaltose [Injectafer] 750 mg IV; B12/folate deficiency; GI bleed → endoscopy)

• HTN emergency: nicardipine (Cardene) 5 mg/hr IV → titrate by 2.5 mg/hr q5–15 min (max 15 mg/hr) or clevidipine (Cleviprex) 1–2 mg/hr IV → double q90 sec (max 21 mg/hr); target 20–25% MAP↓ in first 1–2h; if pulmonary edema component → nitroglycerin (NTG/Nitro-Bid) 5–200 mcg/min IV; if aortic dissection → esmolol (Brevibloc) 500 mcg/kg IV bolus → 50–200 mcg/kg/min (anti-impulse) + nicardipine (Cardene)

• Severe hypoxemia: supplemental O2 to SpO2 ≥94%; if inadequate → NIV: BiPAP IPAP 10–14/EPAP 5–8 cm H2O; if NIV fails or AMS → intubation with lung-protective ventilation (TV 6 mL/kg IBW, PEEP 5–8, FiO2 minimum to SpO2 ≥94%); treat underlying cause (ARDS → dexamethasone 6 mg IV daily [RECOVERY: ↓mortality 28%]; PE → anticoag ± thrombolytics)

• Coronary vasospasm: nitroglycerin (NTG SL) 0.4 mg SL q5 min ×3 + CCB (diltiazem [Cardizem] 60–120 mg PO TID or amlodipine [Norvasc] 5–10 mg PO daily); cocaine-induced — avoid BB (unopposed alpha → ↑vasospasm); nitroglycerin (NTG) + benzodiazepine (lorazepam [Ativan] 1–2 mg IV) + CCB; phentolamine (Regitine) 5 mg IV for refractory vasospasm (alpha-blocker → vasodilation)

• Takotsubo CM management: avoid catecholamines/inotropes (dobutamine [Dobutrex]/epinephrine [Adrenalin] — worsen catecholamine-induced myocardial stunning); if cardiogenic shock → IABP (Datascope) or Impella CP (Abiomed) bridge; BB (metoprolol succinate [Toprol-XL] 12.5–25 mg PO daily — ↑EF recovery) + ACEi (lisinopril [Zestril] 2.5–5 mg PO daily); anticoag if apical thrombus on echo → apixaban (Eliquis) 5 mg PO BID or warfarin (Coumadin) INR 2–3 ×3–6 months; EF reassessment at 4–6 weeks (usually recovers fully); do NOT implant ICD until EF fully reassessed at 3 months

• Serial troponin decision algorithm:

  • "Is the troponin declining with precipitant treatment?" = single most important daily question

  • YES at 12–24h → Type 2 confirmed → continue treating precipitant; reassess at 24h

  • NO at 12–24h (troponin still rising or plateau without decline) → cardiology consult + consider coronary angiography

  • Indications for cath in Type 2 context: (1) troponin rising disproportionately (>20× URL); (2) classic ischemic symptoms independent of illness; (3) focal territorial ECG changes; (4) new focal WMA in coronary territory on echo; (5) hemodynamic instability despite adequately treated precipitant

• Medical therapy: aspirin (Bayer) 81 mg PO daily if CAD RF present; atorvastatin (Lipitor) 40–80 mg PO daily; do NOT add P2Y12 without cath-confirmed obstructive CAD treated with PCI + cardiology guidance

• PT/OT eval and treat — treat underlying illness first; mobilize when medically stable; fall risk assessment; functional capacity evaluation

• Trend daily: serial troponin q6–8h until clear declining trend documented ("Is it going down?" is the only question); serial ECG (daily + with any symptom change); CBC (Hgb — transfusion decision; WBC — infection); BMP (Cr/K+); lactate (sepsis clearance q4–6h); fever curve; hemodynamic parameters

• Escalation triggers: troponin continues rising OR re-elevates after 12–24h of adequate precipitant treatment → cardiology + coronary angiography · new focal STE at any time → STEMI protocol immediately (do not be distracted by "there's a clear precipitant") · new focal WMA on echo → urgent cardiology + cath · hemodynamic deterioration despite treated precipitant → CCU + MCS · cocaine-induced refractory vasospasm → phentolamine (Regitine) 5 mg IV + cardiology · Takotsubo + cardiogenic shock + inotrope resistance → Impella (Abiomed) or IABP (Datascope)

• Discharge: treat underlying illness to resolution; aspirin (Bayer) 81 mg PO daily; atorvastatin (Lipitor) 40–80 mg PO daily; address precipitant cause: AF → DOAC + rate control agent; anemia → IV ferric carboxymaltose (Injectafer) 750 mg IV or PO ferrous sulfate (Feosol) 325 mg TID; HTN → antihypertensive regimen (ACEi + CCB + thiazide); OSA → formal sleep study + CPAP; cocaine → addiction medicine consult; DO NOT prescribe routine DAPT unless cath-confirmed obstructive CAD was treated with PCI and cardiology guided initiation; cardiology f/u 4–6 weeks; Takotsubo → echo at 6 weeks (EF recovery); return precautions: chest pain + diaphoresis + palpitations + syncope

⚠ Red Flags

• Troponin elevation misclassified as Type 2 MI when Type 1 (NSTEMI/STEMI) is actually present — the most dangerous error; in patients with severe underlying CAD, Type 1 and Type 2 can coexist; focal territorial ECG changes or regional WMA on echo mandate Type 1 workup regardless of apparent precipitant

• New focal STE developing during Type 2 MI management → STEMI protocol immediately; do not dismiss as "demand ischemia ECG changes" — focal STE is a Type 1 emergency regardless of the clinical context

• Reflexive urgent cath for all elevated troponins in hospitalized patients → contrast nephropathy + vascular access complications + unnecessary DAPT + ↑bleeding in ill patients; Type 2 MI = most common MI type in non-cardiac hospitalized patients; serial troponin kinetics + echo + clinical context determine need for cath

• Inotropes (dobutamine [Dobutrex]/epinephrine [Adrenalin]) in Takotsubo CM → ↑catecholamine surge → worsens apical ballooning → cardiogenic shock paradox; use IABP (Datascope) or Impella (Abiomed) instead for mechanical circulatory support

• BB in cocaine-induced Type 2 MI → unopposed alpha-adrenergic stimulation → coronary vasospasm + ↑systemic vascular resistance → ↑MI burden; use NTG + lorazepam (Ativan) + CCB instead; phentolamine (Regitine) for refractory vasospasm

• DAPT loading without cath-confirmed obstructive CAD in Type 2 MI + active GI bleed or recent surgery → major bleeding complication; always confirm obstructive CAD by coronary angiography before DAPT in Type 2 context

• Troponin in sepsis misinterpreted as cardiac emergency → troponin elevated in 60% of sepsis patients from cytokine-mediated injury; treatment = sepsis management; reserve cath for troponin rising disproportionately, focal ECG changes, focal WMA on echo, or hemodynamic instability despite resuscitation

Senior IM Resident Pearls

• 4th Universal MI Definition (2018) — Type 2 MI: MI from supply/demand mismatch without coronary thrombosis; defined by: troponin rise above 99th percentile URL + ischemic symptoms/ECG changes/echo WMA consistent with ischemia + a clear mechanism of supply/demand imbalance; most common MI type in non-cardiac hospitalized patients; frequently mismanaged in both directions (missed as cardiac event vs overtreated with unnecessary DAPT + cath)

• DAPT NOT indicated for Type 2 MI without confirmed obstructive CAD: PLATO/TRITON/CURE all enrolled Type 1 ACS patients with coronary thrombus; DAPT in Type 2 MI without obstructive CAD → ↑bleeding risk in common precipitants (GI bleed, post-surgery, sepsis, thrombocytopenia) without proven ischemic benefit; always confirm obstructive CAD by coronary angiography before DAPT

• Troponin kinetics — the key diagnostic tool: Type 2 = modest rise + clear precipitant + declining within 12–24h of adequate precipitant treatment; Type 1 = disproportionately high rise OR failing to decline at 12–24h; a single troponin value cannot distinguish Type 1 from Type 2; serial troponin kinetics + echo WMA assessment + clinical context = the correct diagnostic approach; "Is it going down?" = most important daily question

• MINT trial (2023, NEJM): liberal transfusion (Hgb ≥10 g/dL) vs restrictive (Hgb ≥8 g/dL) in anemia + ACS → liberal strategy ↓30-day MACE (14.6% vs 16.7%; NNT 50); use Hgb ≥10 g/dL as transfusion target in Type 2 MI + anemia; evidence from MINT supports less restrictive transfusion in this population than general ICU patients

• Takotsubo CM — avoid inotropes: catecholamine-mediated pathophysiology; dobutamine (Dobutrex) and epinephrine (Adrenalin) worsen apical ballooning by ↑catecholamine effect; use IABP (Datascope) or Impella CP (Abiomed) for mechanical support if cardiogenic shock; EF recovers in 4–6 weeks in vast majority; LV thrombus in ~4% → anticoag; do NOT implant ICD until EF reassessed at 3 months (most patients do not need ICD)

• Cocaine-induced Type 2 MI — never give BB alone: cocaine blocks catecholamine reuptake → alpha + beta stimulation; BB alone → blocks beta → unopposed alpha → ↑coronary vasospasm + ↑systemic vascular resistance → ↑MI burden; correct treatment: nitroglycerin (NTG SL) + lorazepam (Ativan) + CCB (diltiazem [Cardizem] or amlodipine [Norvasc]); phentolamine (Regitine) 5 mg IV for refractory vasospasm (pure alpha-blocker)

• Troponin in sepsis — not an automatic cardiac emergency: elevated in 60% of septic patients; mechanism = cytokine-mediated myocardial injury + microvascular dysfunction + ↑demand; independent predictor of in-hospital mortality (OR ~2–3); treatment is sepsis management; indications for cath in sepsis + troponin: troponin rising disproportionately, focal ECG changes, regional WMA on echo, hemodynamic instability despite adequate resuscitation

• Common mistake — reflexive urgent cath for all elevated troponins: Type 2 MI significantly overtreated with unnecessary coronary angiography; correct algorithm: (1) identify precipitant; (2) serial troponin kinetics; (3) bedside echo (focal WMA?); (4) serial ECG; (5) cath only if Type 1 cannot be excluded; reflexive cath in septic/bleeding/post-surgical patients → contrast nephropathy + vascular complications + unnecessary DAPT + bleeding complications